Business Context and Reporting Period
Company: Prana Biotechnology Limited (Note: Metadata listed "Alterity Therapeutics" but filing text confirms Prana Biotechnology Limited).
Filing Type: Form 6-K (Preliminary Final Report under ASX Listing Rule 4.2A).
Reporting Period: Financial year ended 30 June 2016.
Principal Activities: Commercialization of research into Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The Group operates primarily in Australia.
Key Financial Metrics
| Metric | 2016 (A$) | 2015 (A$) |
|---|---|---|
| Revenue | 142,657 | 176,842 |
| Other Income (R&D Tax Incentive) | 4,753,697 | 6,317,438 |
| Net Loss | (7,729,551) | (5,885,069) |
| Operating Cash Flow | (7,418,526) | (10,871,074) |
| Cash and Cash Equivalents | 28,593,538 | 34,909,574 |
| Total Assets | 33,725,020 | 41,834,382 |
| Total Liabilities | 2,357,807 | 2,721,118 |
| Net Tangible Assets per Share | 5.88 cents | 7.33 cents |
| Loss per Share (Basic) | (1.45) cents | (1.17) cents |
Debt and Liquidity: The company reported no borrowings or interest-bearing debt. Total liabilities consist primarily of trade payables and provisions. Cash reserves decreased by approximately A$6.3 million year-over-year.
Material Changes vs. Prior Period
- Revenue: Decreased 19.33% to A$142,657. Revenue consists solely of interest income on bank accounts.
- Net Loss: Increased 31.34% to A$7.73 million. The increase is attributed to lower foreign exchange gains and a decrease in R&D tax incentive income, partially offset by reduced R&D expenditure.
- R&D Expenses: Decreased 22.03% to A$9.59 million (from A$12.30 million). This reduction is primarily due to the FDA placing the lead candidate PBT2 on a partial clinical hold.
- Other Income: Decreased to A$4.75 million, driven by a lower R&D tax incentive rebate compared to the prior year.
- Foreign Exchange: Significant decrease in foreign exchange gains from A$4.72 million in 2015 to A$0.86 million in 2016.
Outlook, Risks, and Management Commentary
Clinical Development Status
- PBT2 (Huntington's Disease): Development is ongoing to address a Partial Clinical Hold issued by the US FDA. The company is preparing a Phase 3 protocol for FDA submission and compiling data for European authorities (EMA). Recent patient-reported outcomes from the Reach2HD trial indicated 90% of improvements in "problems with thinking" were achieved with PBT2-treated patients.
- PBT434 (Parkinsonian Movement Disorders): Progressed through mouse models showing decreased toxic protein levels and improved motor/cognitive performance. Non-clinical toxicity studies are complete, and a Phase 1 program plan is being compiled for FDA submission.
- Pipeline: Additional candidates are being profiled through the Translational Biology Program to diversify the pipeline for neurodegenerative disorders.
Risks and Contingencies
- Regulatory Risk: The partial clinical hold on PBT2 by the FDA limits dosing in future US trials and has directly impacted R&D spending and cash flow.
- Liquidity Risk: The company is pre-revenue (operating revenue is negligible interest income) and relies on cash reserves and R&D tax incentives. Cash burn was A$7.42 million for the year.
- Audit Status: As of the filing date (August 26, 2016), the accounts were in the process of being audited.
Investor Verification Checklist
- Regulatory Resolution: Verify the status of the FDA Partial Clinical Hold on PBT2 and the timeline for lifting the hold or approval of the Phase 3 protocol.
- Cash Runway: Assess the remaining cash reserves (A$28.6 million) against the current burn rate to determine the need for future capital raises.
- R&D Tax Incentive: Confirm the eligibility and timing of the A$4.8 million R&D tax incentive receivable, which is a material component of the company's income.
- Audit Completion: Review the final audited Annual Report once issued to confirm the preliminary figures presented in this 6-K.
- PBT434 Progress: Monitor the submission and acceptance of the Phase 1 IND application for PBT434.